Cargando…

Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals

The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk(®)), estimates CV risk throughout a subjects’ lifetime, allowing those....

Descripción completa

Detalles Bibliográficos
Autores principales: Baldan-Martin, Montserrat, Lopez, Juan A., Corbacho-Alonso, Nerea, Martinez, Paula J., Rodriguez-Sanchez, Elena, Mourino-Alvarez, Laura, Sastre-Oliva, Tamara, Martin-Rojas, Tatiana, Rincón, Raul, Calvo, Eva, Vazquez, Jesus, Vivanco, Fernando, Padial, Luis R., Alvarez-Llamas, Gloria, Ruiz-Hurtado, Gema, Ruilope, Luis M., Barderas, Maria G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859270/
https://www.ncbi.nlm.nih.gov/pubmed/29555916
http://dx.doi.org/10.1038/s41598-018-23037-7
_version_ 1783307788068323328
author Baldan-Martin, Montserrat
Lopez, Juan A.
Corbacho-Alonso, Nerea
Martinez, Paula J.
Rodriguez-Sanchez, Elena
Mourino-Alvarez, Laura
Sastre-Oliva, Tamara
Martin-Rojas, Tatiana
Rincón, Raul
Calvo, Eva
Vazquez, Jesus
Vivanco, Fernando
Padial, Luis R.
Alvarez-Llamas, Gloria
Ruiz-Hurtado, Gema
Ruilope, Luis M.
Barderas, Maria G.
author_facet Baldan-Martin, Montserrat
Lopez, Juan A.
Corbacho-Alonso, Nerea
Martinez, Paula J.
Rodriguez-Sanchez, Elena
Mourino-Alvarez, Laura
Sastre-Oliva, Tamara
Martin-Rojas, Tatiana
Rincón, Raul
Calvo, Eva
Vazquez, Jesus
Vivanco, Fernando
Padial, Luis R.
Alvarez-Llamas, Gloria
Ruiz-Hurtado, Gema
Ruilope, Luis M.
Barderas, Maria G.
author_sort Baldan-Martin, Montserrat
collection PubMed
description The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk(®)), estimates CV risk throughout a subjects’ lifetime, allowing those. A more aggressive and earlier intervention to be identified and offered protection from the consequences of CV and renal disease. The search for molecular profiles in young people that allow a correct stratification of CV risk would be of great interest to adopt preventive therapeutic measures in individuals at high CV risk. To improve the selection of subjects susceptible to intervention with aged between 30–50 years, we have employed a multiple proteomic strategy to search for new markers of early CV disease or reported CV events and to evaluate their relationship with Lifetime Risk. Blood samples from 71 patients were classified into 3 groups according to their CV risk (healthy, with CV risk factors and with a previously reported CV event subjects) and they were analyzed using a high through quantitative proteomics approach. This strategy allowed three different proteomic signatures to be defined, two of which were related to CV stratification and the third one involved markers of organ damage.
format Online
Article
Text
id pubmed-5859270
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58592702018-03-20 Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals Baldan-Martin, Montserrat Lopez, Juan A. Corbacho-Alonso, Nerea Martinez, Paula J. Rodriguez-Sanchez, Elena Mourino-Alvarez, Laura Sastre-Oliva, Tamara Martin-Rojas, Tatiana Rincón, Raul Calvo, Eva Vazquez, Jesus Vivanco, Fernando Padial, Luis R. Alvarez-Llamas, Gloria Ruiz-Hurtado, Gema Ruilope, Luis M. Barderas, Maria G. Sci Rep Article The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk(®)), estimates CV risk throughout a subjects’ lifetime, allowing those. A more aggressive and earlier intervention to be identified and offered protection from the consequences of CV and renal disease. The search for molecular profiles in young people that allow a correct stratification of CV risk would be of great interest to adopt preventive therapeutic measures in individuals at high CV risk. To improve the selection of subjects susceptible to intervention with aged between 30–50 years, we have employed a multiple proteomic strategy to search for new markers of early CV disease or reported CV events and to evaluate their relationship with Lifetime Risk. Blood samples from 71 patients were classified into 3 groups according to their CV risk (healthy, with CV risk factors and with a previously reported CV event subjects) and they were analyzed using a high through quantitative proteomics approach. This strategy allowed three different proteomic signatures to be defined, two of which were related to CV stratification and the third one involved markers of organ damage. Nature Publishing Group UK 2018-03-19 /pmc/articles/PMC5859270/ /pubmed/29555916 http://dx.doi.org/10.1038/s41598-018-23037-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Baldan-Martin, Montserrat
Lopez, Juan A.
Corbacho-Alonso, Nerea
Martinez, Paula J.
Rodriguez-Sanchez, Elena
Mourino-Alvarez, Laura
Sastre-Oliva, Tamara
Martin-Rojas, Tatiana
Rincón, Raul
Calvo, Eva
Vazquez, Jesus
Vivanco, Fernando
Padial, Luis R.
Alvarez-Llamas, Gloria
Ruiz-Hurtado, Gema
Ruilope, Luis M.
Barderas, Maria G.
Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
title Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
title_full Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
title_fullStr Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
title_full_unstemmed Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
title_short Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
title_sort potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859270/
https://www.ncbi.nlm.nih.gov/pubmed/29555916
http://dx.doi.org/10.1038/s41598-018-23037-7
work_keys_str_mv AT baldanmartinmontserrat potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT lopezjuana potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT corbachoalonsonerea potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT martinezpaulaj potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT rodriguezsanchezelena potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT mourinoalvarezlaura potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT sastreolivatamara potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT martinrojastatiana potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT rinconraul potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT calvoeva potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT vazquezjesus potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT vivancofernando potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT padialluisr potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT alvarezllamasgloria potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT ruizhurtadogema potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT ruilopeluism potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals
AT barderasmariag potentialroleofnewmolecularplasmasignaturesoncardiovascularriskstratificationinasymptomaticindividuals